Compare AHRT & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AHRT | ACRS |
|---|---|---|
| Founded | 1979 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 471.1M | 529.9M |
| IPO Year | 2013 | 2015 |
| Metric | AHRT | ACRS |
|---|---|---|
| Price | $5.99 | $3.45 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 12 |
| Target Price | $7.50 | ★ $9.82 |
| AVG Volume (30 Days) | 688.0K | ★ 2.6M |
| Earning Date | 11-02-2026 | 11-05-2026 |
| Dividend Yield | ★ 9.16% | N/A |
| EPS Growth | N/A | ★ 69.01 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $285,201,000.00 | $1,683,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.96 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.13 | $2.46 |
| 52 Week High | $7.20 | $6.60 |
| Indicator | AHRT | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 41.50 | 39.18 |
| Support Level | $5.87 | $3.24 |
| Resistance Level | $6.17 | $4.60 |
| Average True Range (ATR) | 0.17 | 0.28 |
| MACD | -0.04 | -0.02 |
| Stochastic Oscillator | 2.60 | 17.03 |
AH Realty Trust Inc is a real estate investment trust (REIT). It owns, operates, and acquires high-quality properties across the Mid-Atlantic and Southeast, creating lasting value for investors, partners, clients, tenants, and communities. The group focuses on operating and acquiring high-quality, well-positioned assets with growth potential and delivering long-term value for shareholders. Its portfolio includes Harbor Point, Southern Post, The Interlock, and Others.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.